Key result
Shared upstream cellular pathways link type 2 diabetes and cardiovascular disease, highlighting dual therapeutic targets.
The interactions between cardiovascular disease (CVD) and insulin resistance syndromes suggest the possibility of joint targets for cardiometabolic research. The best drugs would go beyond minimizing adverse effects and have protective actions against both metabolic disease and CVD. In this perspective, we will outline a few examples in which a deep mechanistic understanding of the many cellular pathways that contribute to type 2 diabetes and CVD, regardless of cell type, have resulted in common upstream pathogenic pathways that can be therapeutically targeted.
No takes yet. Share an insight, caveat, or question.
Fredman et al. (2014) conducted a review in Cardiometabolic disease (cardiovascular disease and type 2 diabetes). Therapeutic targeting of common upstream pathogenic pathways was evaluated. Common upstream cellular pathways contributing to both type 2 diabetes and cardiovascular disease represent potential shared therapeutic targets in this mechanistic perspective.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: